Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
Gene-Edited ‘Supercells’ Make Progress In Fight Against Sickle Cell DiseaseDoctors are reporting the first evidence...
-
Guy’s and St Thomas’ NHS Foundation TrustOur haemoglobinopathies service sees chi...
-
Charles Jonassaint, PhDDr. Jonassaint is a practicing clinical ...
-
Methodist Comprehensive Sickle Cell CenterMethodist Comprehensive Sickle Cell Cent...
-
Barbara Yawn, MDBarbara P. Yawn, MD, MSc, FAAFP, is Adju...
-
Family functioning, medical self-management, and health outcomes among school-aged children with sickle cell disease...BACKGROUND: Informed by the Pediatric S...
-
Managing Sickle Cell Disease as an AdultPeople with sickle cell disease (SCD) ar...
